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Common genetic variants have been identified for adult height, but not much is known about the genetics of
skeletal growth in early life. To identify common genetic variants that influence fetal skeletal growth, we meta-
analyzed 22 genome-wide association studies (Stage 1; N 5 28 459). We identified seven independent top
single nucleotide polymorphisms (SNPs) (P < 1 3 1026) for birth length, of which three were novel and four
were in or near loci known to be associated with adult height (LCORL, PTCH1, GPR126 and HMGA2). The
three novel SNPs were followed-up in nine replication studies (Stage 2; N 5 11 995), with rs905938 in DC-
STAMP domain containing 2 (DCST2) genome-wide significantly associated with birth length in a joint analysis
(Stages 1 1 2; b 5 0.046, SE 5 0.008, P 5 2.46 3 1028, explained variance 5 0.05%). Rs905938 was also asso-
ciated with infant length (N 5 28 228; P 5 5.54 3 1024) and adult height (N 5 127 513; P 5 1.45 3 1025). DCST2
is a DC-STAMP-like protein family member and DC-STAMP is an osteoclast cell-fusion regulator. Polygenic
scores based on 180 SNPs previously associated with human adult stature explained 0.13% of variance in
birth length. The same SNPs explained 2.95% of the variance of infant length. Of the 180 known adult height
loci, 11 were genome-wide significantly associated with infant length (SF3B4, LCORL, SPAG17, C6orf173,
PTCH1, GDF5, ZNFX1, HHIP, ACAN, HLA locus and HMGA2). This study highlights that common variation in
DCST2 influences variation in early growth and adult height.
INTRODUCTION
Fetal and infancy length growth are important measures of de-
velopment in early life. Early length growth seems to be asso-
ciated with height in adulthood (1). It has been shown that
fetal and infant growth are independently associated with
higher risks of cardiovascular disease, type 2 diabetes and
many other complex diseases. Previous findings suggested
genetic links between fetal growth and metabolism (2,3).
However, these studies mainly focused on birth weight as
early growth measure. Skeletal growth is a different measure
of development in early life. Skeletal growth during fetal life
and infancy is a complex trait with heritability estimates of
26–72% (4). Although correlated with each other, fetal, infant
and adult skeletal growth may be influenced by different
genetic factors. Many common genetic variants have been iden-
tified for adult height (5), but not much is known about the gen-
etics of skeletal growth in early life. Although, several rare
genetic defects with large effects on length at birth and during
infancy have been found (6,7), common genetic variants that in-
fluence normal variation in birth and infant length have not yet
been identified. Therefore, we aimed to identify common
genetic variants influencing early length growth, also in perspec-
tive of their effect on adult stature.
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RESULTS
To identify common genetic variants associated with birth
length, we examined 2 201 971 million directly genotyped and
imputed SNPs with birth length in 22 independent discovery
studies with genome-wide association (GWA) or Metabochip
data (Stage 1; N ¼ 28 459; Fig. 1). Birth length was measured
using standardized procedures (Supplementary Material, Tables
S1 and S2). Studies with self-reported measurements were
excluded a priori. Birth length was standardized using growth
analyzer (http://www.growthanalyser.org), transforming birth
length into sex- and age-adjusted standard deviation scores
(SDS). We used the North-European 1991 reference panel to
compare results between studies. We applied linear regression
between number of alleles or dosages obtained from imputations
and standardized birth length (full details in Materials and
Methods).
Gene identification
In the discovery phase (Stage 1), we found seven independent
top SNPs with suggestive evidence of association (P, 1× 1026)
with birth length (Supplementary Material, Figs. S1 and S2,
QQ- and Manhattan plot). Four SNPs mapped to loci already
known to be associated with adult height (Supplementary Mater-
ial, Table S3, LCORL, PTCH1, GPR126 and HMGA2) (5). The 3
SNPs reflecting potentially novel associations were taken for-
ward in nine independent replication studies (Stage 2; N ¼ 11
995; Fig. 1). Only one of the three SNPs displayed significant
evidence for replication in Stage 2 and reached genome-wide
significance in the joint analysis (Stages 1 + 2; P , 5 × 1028;
Table 1). This novel association arose from SNP rs905938,
mapping to chromosome 1q22 in DC-STAMP domain contain-
ing 2 (DCST2) (Fig. 2, regional association plot). Each C allele
[minor allele frequency (MAF) ¼ 0.24] of rs905938 was asso-
ciated with an increase (standardized) of 0.046 SDS in birth
length (standard error ¼ 0.008, P ¼ 2.46 × 1028; explained
variance ¼ 0.05%). The genome-wide significantly associated
SNP showed low degree of heterogeneity between the discovery
studies (P ¼ 0.93, I2 ¼ 0%). Figure 3 shows the forest plot of the
associations between rs905938[C] and birth length across all
studies. Other suggestive loci in the discovery analysis are
shown in Supplementary Material, Table S3 (P , 1 × 1025).
Summary statistics of all SNPs are available at http://egg-
consortium.org.
Functional analyses
We assessed common variants with deleterious functional impli-
cations in linkage disequilibrium (LD, r2. 0.80) with rs905938
using HaploReg (8). There were no non-synonymous variants in
LD with rs905938. We found three putative functional intronic
variants in high LD with rs905938. Details are depicted in Sup-
plementary Material, Table S4. Subsequently, we assessed
whether variants in the identified locus were involved in the
Figure 1 Study design.
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regulation of messenger RNA expression (eQTLs) in genome-
wide expression datasets of lymphoblastoid cell lines (LCLs,
N ¼ 1830) (9,10). We found cis eQTLs [false discovery rate
(FDR), 1% account for all SNP-probe pairs that were within
1 Mb of each other) for transcripts of PBXIP1, GBA and
ADAM15. Yet, rs905938 and the cis eQTL SNPs were not in
perfect LD (r2 , 0.80, Supplementary Material, Table S5).
Therefore, we cannot exclude that multiple independent effects
arise from the same region of association.
DCST2 and growth phenotypes
We tested the associations of rs905938[C] with ‘fetal growth’
measures in the 1st, 2nd and 3rd trimester of pregnancy in the
Table 1 Summary statistics of the three novel SNPs at P, 1 × 1026 in the discovery analysis and the replication follow-up results
Marker MAF b SE P n I2 HetP
Discovery (Stage 1)
rs905938[C] at 1q22 (DCST2) 0.24 0.050 0.010 2.59 × 1027 28 327 0.0 0.930
rs12545524[G] at 8q22.1 (near GDF6) 0.14 0.078 0.014 1.54 × 1028 22 170 6.6 0.376
rs11037473[A] at 11p11.2 (nearest genes TTC17-HSD17B12) 0.06 20.109 0.021 2.17 × 1027 22 259 0.0 0.735
Replication (Stage 2)
rs905938[C] at 1q22 (DCST2) 0.23 0.035 0.015 1.99 × 1022 11 908 – –
rs12545524[G] at 8q22.1 (near GDF6) 0.11 20.012 0.017 4.67 × 1021 17 614 – –
rs11037473[A] at 11p11.2 (nearest genes TTC17-HSD17B12) 0.08 20.035 0.020 8.06 × 1022 17 606 – –
Discovery + replication (Stages 1 + 2)
rs905938[C] at 1q22 (DCST2) 0.24 0.046 0.008 2.46 × 1028 40 235 – –
rs12545524[G] at 8q22.1 (near GDF6) 0.13 0.042 0.011 9.08 × 1025 39 784 – –
rs11037473[A] at 11p11.2 (nearest genes TTC17-HSD17B12) 0.07 20.069 0.014 1.49 × 1026 39 865 – –
SNPs markers are identified according to their standard rs numbers (NCBI build 36). Independent novel SNPs with a strong suggestive effect in the discovery analysis
on birth length are shown (P , 1 × 1026). SNPs in loci that are known to be associated with adult height were excluded for replication efforts (adult height loci:
LCORL, PTCH1, GPR126 and HMGA2). MAF, minor allele frequency; SE, standard error.b reflects differences in standardized birth length per minor allele. P values
are obtained from linear regression of each SNP against standardized birth length adjusted for sex and gestational age. We included both GWA and metabochip cohorts
in our discovery analysis, rs905938 is on the metabochip, and rs12545524 and rs11037473 are not, this explains the differences in numbers (n). Derived inconsistency
statistic I2 and HetP values reflect heterogeneity across discovery studies with the use of Cochran’s Q tests.
Figure2Regional association plot of 1q22 in the 22 birth length discovery studies (N ¼ 28 459). SNPs are plotted with their P values (as2log10 values; left y-axis) as a
function of genomic position (x-axis). Estimated recombination rates (right y-axis) taken from HapMap are plotted to reflect the local LD-structure around the top
associated SNP (‘white open diamond’) and the correlatedproxies (‘circles’ according to a black-to-gray scale from r2 ¼ 0 to 1). The joint analysis P valueof discovery
and replication studies is reported with the ‘white square’ (N ¼ 40 235).
Human Molecular Genetics, 2015, Vol. 24, No. 4 1159
Downloaded from https://academic.oup.com/hmg/article-abstract/24/4/1155/616707
by kingstonuni user
on 11 December 2017
Generation R Study (N ¼ 5756) (11), infant length at 1 year of
age (range 6–18 months; N ¼ 28 228) in the Early Growth
Genetics (EGG) consortium (12), and adult height in the
Genetic Investigation of Anthropometric Traits (GIANT) con-
sortium (N ¼ 127 513) (5). Rs905938[C] was not associated
with ‘fetal growth’ measures, but was associated with infant
length and adult height (P , 0.05; Table 2).
Known adult height loci in relation to birth and infant length
We also explored whether common genetic variants known to be
associated with adult height (5) influenced birth length variation.
We found that 17 out of 180 known adult height loci were asso-
ciated with birth length (FDR , 5%, Supplementary Material,
Table S6; Fig. 4, QQ-plot of 180 SNPs and birth length). We
then calculated a height-increasing-alleles score of the 180
known height loci (5) to predict birth length in the Generation
R Study (N ¼ 2085; Fig. 5). The score composed of variants
associated with adult height explained 0.13% of the variance
in birth length (P ¼ 0.1), in contrast to the 10% of the
phenotypic variation in adult height reported in the original
manuscript (5).
To evaluate whether different common genetic variants influ-
enced both birth and infant length, we tested 2 193 675 million
SNPs for association with infant length in almost the same set
of samples used for the analysis of birth length (19 studies,
N ¼ 28 238; Supplementary Material, Table S7). We identified
genome-wide significant associations at 11 genetic loci (Supple-
mentary Material, Figs S3 and S4, QQ- and Manhattan plot),
which all are known to be associated with adult height
(Table 3, SNPs in or near SF3B4, LCORL, SPAG17, C6orf173,
PTCH1, GDF5, ZNFX1, HHIP, ACAN, HLA locus and HMGA2)
(5,13). In addition, we found that variants in 58 of the adult
height loci were associated with infant length at an FDR of 5%
(Supplementary Material, Table S8; Fig. 4, QQ-plot of 180
SNPs and infant length). Next, we tested in the Generation R
Study (N ¼ 2385) how much of the phenotypic variance in
infant length was explained by the score composed of height-
increasing-alleles. Variants from the 180 known adult height
loci together explained 2.95% of the variance in infant length
(P ¼ 3.10 × 10217, Fig. 5).
DEPICT analysis of birth and infant length
Finally, we used a pathway analysis tool called DEPICT (Pers
et al., unpublished data) to prioritize genes at associated regions,
search for reconstituted gene sets that were enriched in genes
near associated variants, and identify tissue and cell types in
which genes from loci associated with birth and infant length
were highly expressed (full details in Materials and Methods).
For both traits, we used independent SNPs (r2, 0.05) asso-
ciated at P, 1 × 1025, from 21 birth length and 44 infant
length loci. There were no pathways significantly overrepre-
sented in the birth length results. In contrast, for infant length
DEPICT significantly prioritized nine genes which were overre-
presented (FDR , 5%, Supplementary Material, Table S9),
including three known Mendelian human stature genes (ACAN,
GDF5 and PTCH1) as well as several relevant reconstituted
Figure 3 Forest plot of the associations between rs905938[C] and birth length.
∗Replication studies. The ‘black diamond’ indicates the overall effect size and
the confidence interval of the 31 studies.
Table 2 Associations of rs905938[C] in DCST2 related to birth length with ‘fetal
growth’ measures, infant length and adult height
b SE P
Generation R: fetal growth (N ¼ 5756)
First trimester
Crown-rump length (n ¼ 1126) 0.003 0.045 0.952
Second trimester
Femur length (n ¼ 5361) 20.035 0.023 0.129
Third trimester
Femur length (n ¼ 5532) 20.015 0.022 0.490
EGG: infant length
Infant length at 1 year of age (N ¼ 28 228) 0.035 0.010 5.54 × 1024
GIANT: adult height
Adult height (N ¼ 127 513) 0.024 0.006 1.45 × 1025
rs905938 C-allele with a genome-wide significant effect on birth length is shown
(P , 5 × 1028) in relation to ‘fetal growth’ measures, infant length and adult
height. SE, standard error. b reflects difference in standard deviation scores per
minor allele.
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gene sets (e.g. abnormal sternum ossification, regulation of
osteoblast proliferation and WNT signaling, Supplementary
Material, Table S10). There was no significant enrichment for
particular tissue or cell types for any of the two traits.
DISCUSSION
In the present study we identified one previously unknown locus
(rs905938 in DCST2 at 1q22) to be associated with birth length at
a genome-wide significant level. This common genetic variant
was also associated with infant length and adult height.
It was not possible to identify eQTLs for transcripts of DCST2
in the MRCA and MRCE databases, as there were no probes
available (9). Also, there was no significant eQTL of DCST2 in
immortalized LCLs (10). However, DCST2 is a DC-STAMP-
like protein family member and DC-STAMP is an important
regulator of osteoclast cell-fusion in bone homeostasis (14–16).
The transcripts of PBXIP1, GBA and ADAM15 were in weak
LD with our lead SNP rs905938. The PBXIP1 protein is known
to regulate estrogen receptor functions (17). Mutations in the
GBA gene cause Gaucher disease, and strong associations with
Parkinson’s disease and dementia with Lewy bodies have been
described (18–21). ADAM15 is prominently expressed in osteo-
blasts and to a lesser extent in osteoclasts (22). A study in mice
showed that ADAM15 is required for normal skeletal homeosta-
sis and that its absence causes increased nuclear translocation of
b-catenin in osteoblasts leading to increased osteoblast prolifer-
ation and function, which results in higher trabecular and cortical
bone mass (23). The 1q22 locus is a complex region harboring
multiple interesting genes that could affect birth length. We em-
phasize that we could not specifically pinpoint the causal gene(s)
as our lead SNP (rs905938) was not in perfect LD with our cis
eQTL SNPs.
Although, there is some overlap between adult height loci and
birth length, which is illustrated by 17 shared loci, the genetic
architecture of adult height seems more similar to the genetic
architecture of infant length than birth length [58 shared loci
for infant length, based on conservative statistical method
(FDR)]. One point of consideration for the interpretation of
our findings is the potential of measurement error for birth
length (24). This may lead to less power to detect novel genetic
variants as standard errors of SNPs could be increased. The esti-
mate of the risk-allele score slope of Figure 5 is not influenced
by measurement error and the differences in the slopes suggest
that birth and infant length are influenced by distinct genetic
variants. We found that the SNP effects for birth length of 137
of the 180 established height loci were in the same direction
as reported in the GIANT paper (5) (Supplementary Material,
Table S6; probability of success ¼ 0.761, P ¼ 6.25 × 10213).
One hundred sixty-two of the 180 loci were in the same direction
for infant length (Supplementary Material, Table S8; probability
of success ¼ 0.900, P ¼ 2.20 × 10216).
Four SNPs associated with birth length (P, 1 × 1025) are in
or near loci known to be associated with birth weight (LCORL,
HMGA2, ADCY5 and ADRB1). LCORL is associated with
birth weight, birth length, infant length and adult height, but
we could not find an obvious link between the gene and
adult-onset diseases. HMGA2 is associated with aortic root
size (25), type 2 diabetes (26), and many other traits like tooth
development, head circumference and brain structure (12,27).
ADCY5 is also associated with type 2 diabetes and ADRB1
with adult blood pressure (2,3). These findings highlight genetic
links between fetal growth and metabolism (2,3,26). As we
found overlap between genetic variants of birth weight and birth
length, we looked-up the effect of rs905938 in DCST2 on birth
weight in a previous EGG study (3). Rs905938 was associated
with birth weight, but weaker as compared with birth length
(b ¼ 0.035 SDS, SE ¼ 0.010, P ¼ 2.35 × 1024, N ¼ 26 558).
In conclusion, in the present study we identified one novel
locus (rs905938 in DCST2 at 1q22) associated with birth
length at a genome-wide significant level. This common
Figure 4 QQ-plots of the 180 known adult height SNPs with birth and infant
length. QQ-plot of the 180 known adult height SNPs in association with birth
length (upper panel) in 22 studies (N ¼ 28 459) and with infant length (lower
panel) in 19 studies (N ¼ 28 238). The black dots represent observed P values
and the diagonal lines represent the expected P values under the null distribution.
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genetic variant was also associated with infant length and adult
height, with decreasing magnitude of the associations in later
life (0.046 SDS for birth length, 0.035 SDS for infant length
and 0.024 SDS for adult height). To our knowledge, no pheno-
type has been previously associated with the DCST2 gene and
while the gene is expressed in osteoclasts, its function should
be further studied.
MATERIALS AND METHODS
Stage 1: discovery genome-wide association analyses of birth
length
We combined 21 population-based studies with GWA or Meta-
bochip data and birth length available (total N ¼ 28 459 indivi-
duals). One of our discovery cohorts had two independent
sub-samples within their study leading to a total of 22 independ-
ent GWA/Metabochip sub-samples for our analysis: one sub-
sample from the AvonLongitudinalStudyofParentsandChildren
(ALSPAC, GWA, n ¼ 4816); Children, Allergy, Milieu, Stock-
holm, Epidemiology [Swedish] (BAMSE, GWA, n¼ 423); Chil-
dren’s Hospital Of Philadelphia (CHOP, GWA, n ¼ 432);
Copenhagen Study on Asthma in Childhood 2000 (COPSAC-
2000, GWA, n ¼ 348); Copenhagen Study on Asthma in Child-
hood Registry (COPSAC-Registry, GWA, n ¼ 1111); Danish
National Birth Cohort (DNBC, GWA, n ¼ 932); Generation
R Study (Generation R, GWA, n ¼ 2085); Hyperglycemia and
Adverse Pregnancy Outcomes study (HAPO, GWA, n ¼ 1325);
Helsinki Birth Cohort Study (HBCS, GWA, n ¼ 1572); Infancia
y Medio Ambiente (INMA, GWA, n ¼ 848); Leipzig Childhood
Obesity cohort (LEIPZIG, Metbochip, n ¼ 607); Lifestyle
Immune System Allergy study (LISA, GWA, n ¼ 552);
Figure 5 Height-increasing-alleles score of known adult height SNPs predicting birth and infant length. Genetic risk-allele scores (sum of height-increasing alleles
weighted by known effect on adult height (5) transformed to standard deviation Z-scores) in the Generation R study plotted against length adjusted for sex and age. The
distribution of the genetic risk-allele score is depicted as bars. (A) Mean birth length plotted against the genetic score (N ¼ 2085). (B) Mean infant length plotted
against the genetic score (N ¼ 2385).
Table 3 Summary statistics of the eleven known adult height SNPs in association with infant length at P , 5 × 1028
Marker MAF b SE P n I2 HetP
rs7536458[G] at 1p12 (SPAG17) 0.25 20.064 0.010 9.61 × 10211 28234 0.0 0.403
rs11205303[C] at 1q21.2 (SF3B4) 0.34 0.087 0.011 1.79 × 10216 26559 0.0 0.864
rs1380294[T] at 4p15.31 (LCORL) 0.15 20.108 0.014 2.54 × 10214 23079 13.7 0.184
rs1812175[A] at 4q28-q32(HHIP) 0.18 20.068 0.011 2.33 × 1029 28227 0.0 0.398
rs592229[G] at (HLA locus) 0.43 0.048 0.009 2.22 × 1028 28223 0.6 0.326
rs9385399[T] at 6q22.32 (C6orf173) 0.46 0.055 0.009 1.68 × 10210 28224 0.0 0.943
rs1984119[C] at 9q22.3 (PTCH1) 0.26 20.063 0.010 1.77 × 10210 28197 0.0 0.490
rs7970350[T] at 12q15 (HMGA2) 0.49 20.047 0.009 2.90 × 1028 28226 0.0 0.426
rs2280470[A] at 15q26.1 (ACAN) 0.36 0.053 0.009 6.43 × 1029 27443 0.0 0.436
rs143384[G] at 20q11.2 (GDF5) 0.44 0.058 0.009 2.87 × 10210 28232 0.0 0.996
rs1567865[T] at 20q13.13 (ZNFX1) 0.21 0.063 0.010 1.10 × 1029 28229 22.5 0.104
SNPs markers are identified according to their standard rs numbers (NCBI build 36). The total sample includes data of 19 independent datasets (N ¼ 28 238). MAF,
minorallele frequency;SE, standarderror.b reflects differences in standardized infant length perminor allele. P values are obtained from linear regression of each SNP
against standardized infant length adjusted for sex and age. We included both GWA and metabochip cohorts in our discovery analysis, this explains the differences in
numbers (n). Derived inconsistency statistic I2 and HetP values reflect heterogeneity across discovery studies with the use of Cochran’s Q tests.
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Manchester Asthma and Allergy Study (MAAS, GWA, n ¼ 402);
Norwegian Mother and Child Cohort study (MOBA, GWA,
n ¼ 832); Northern Finland Birth Cohorts 1966 (NFBC66,
GWA, n ¼ 4642); Northern Finland Birth Cohorts 1986
(NFBC86, Metabochip, n ¼ 4652); Physical Activity and Nutri-
tion in Children study (PANIC, Metabochip, n ¼ 319); two sub-
samples from the Prevention and Incidence of Asthma and Mite
Allergy birth cohort study (PIAMA1, GWA, n ¼ 283; PIAMA2,
GWA, n ¼ 195); The Western Australian Pregnancy Cohort
Study (RAINE, GWA, n ¼ 1272); Special Turku Coronary
Risk Factor Intervention Project (STRIP, Metabochip,
n ¼ 614); and TEENs of Attica: Genes and Environment
(TEENAGE, GWA, n ¼ 197). While no systematic phenotypic
differences were observed between the sub-samples of the
PIAMA birth cohort study, they were analyzed separately due
to genotyping on different platforms and at different time
periods. Genotypes within each study were obtained using high-
density SNP arrays and then imputed for2.5 M HapMap SNPs
(Phase II, release 22; http://hapmap.ncbi.nlm.nih.gov/). The
basic characteristics, exclusions applied (for example, indivi-
duals of non-European ancestry, family related individuals),
genotyping, quality control and imputation methods for each dis-
covery study are presented in Supplementary Material, Table S1.
Statistical analysis within discovery studies
In all studies, birth length was measured using standardized pro-
cedures.Studieswithself-reportedmeasurementswereexcluded
a priori. Birth length was standardized using growth analyzer
(http://www.growthanalyser.org), transforming birth length
into sex- and age-adjusted SDS. We used the North-European
1991 reference panel to compare results between studies. Mul-
tiple births and twins were excluded from all analyses. We
applied linear regression between number of alleles or dosages
obtained from imputations and standardized birth length. The
GWA analysis per study was performed using MaCH2qtl (28),
SNPTEST (29), PLINK (30) or PropABEL (31). The secured
data exchange and storage were facilitated by the Erasmus
Medical Center, Department of Internal Medicine (32).
Meta-analysis of discovery studies
Prior tometa-analysis,SNPswithaMAF,0.01andpoorly imputed
SNPs [r2hat ,0.3 (MaCH); proper_info ,0.4 (IMPUTE2);
R2_BEALE ,0.4 (BEAGLE)] were filtered. Genomic control
(GC) (33) was applied to adjust the statistics generated within
each cohort (see Supplementary Material, Table S1 for individ-
ual studylvalues). Four out of the twenty-two sub-samples were
genotyped on Metabochips. These SNP-arrays were enriched
with ‘adult height SNPs’. Normal variation in early length
growth seems to be associated with height in adulthood (1).
Therefore, we assumed more true-positive hits in these studies
and did not apply GC in these studies (GIANT et al., unpublished
data). Details of any additional corrections for study specific
population structure are given in the Supplementary Material,
Table S1. Inverse variance fixed-effects meta-analyses were
analyzed using METAL (released 2010-08-01) (34) by two
meta-analysts in parallel and blinded to obtain identical results.
After the METAL meta-analysis, we filtered SNPs with a MAF
,0.05 and SNPs that were not available in at least 12 sub-
samples to avoid false-positive findings. We used Cochran’s Q
test and the derived inconsistency statistic I2 to assess evidence
of between-study heterogeneity of the effect sizes. The
meta-analysis results were obtained for a total of 2 201 971
SNPs. SNPs that crossed the threshold of P ≤ 1 × 1026 were
considered to represent strong suggestive evidence of associ-
ation with birth length. SNPs that were already known to be asso-
ciated with adult height were excluded for the replication analysis
(5). The explained variance of the top SNPs were calculated in one
of the largest cohorts, the Generation R Study (n ¼ 2085).
Stage 2: replication analysis of top birth length SNPs
In the discovery phase, we found seven independent SNPs with
strong suggestive evidence of association (P, 1 × 1026) with
birth length. Four SNPs were already known to be associated
with adult height (5). These SNPs were excluded for follow-
up analyses. The three remaining novel SNPs were followed-up
in replication studies. We included both GWA and Metabochip
studies in our discovery analysis. Rs905938 was on our Metabo-
chips, and rs12545524 and rs11037473 were not. This results in
differences in numbers for our top SNPs in the discovery and rep-
lication analyses. rs905938 was taken forward in 9 independent
replication studies (N ¼ 11 995), rs12545524 and rs11037473 in
13 independent replication studies including the four discovery
Metabochip studies (N ¼ 17 679). Details of the replication
studies are presented in Supplementary Material, Table S2.
Within the replication studies, we analyzed the association
between number of alleles and standardized birth length. Com-
bined effect estimates and heterogeneity between cohorts was
calculated using fixed effects meta-analyses in R Version 2.8.1
(The R foundation for Statistical Computing, library rmeta).
Top SNPs that crossed the significant threshold of P-replication
≤0.05 and the widely accepted genome-wide significance
threshold of P ≤ 5 × 1028 for all studies combined were consid-
ered to represent robust evidence of association with birth length.
The institutional review boards for human studies approved the
protocols and written consent was obtained from the participat-
ing subjects or their caregivers if required by the institutional
review board.
DEPICT analysis
We used the novel Data-driven Expression-Prioritized Integra-
tion for Complex Traits (DEPICT) method (Pers et al., unpub-
lished data). DEPICT is designed to systematically identify the
most likely causal gene at a given locus, gene sets that are
enriched in genetic associations, and tissues and cell types in
which genes from associated loci are highly expressed. First,
DEPICT assigns genes to associated SNPs using LD r2. 0.5
distance to define locus boundaries, merges overlapping loci
and discards loci mapping within the extended major histocom-
patibility complex region (chromosome 6, base pairs 25 000–
35 000). Next, the DEPICT method prioritizes genes within a
given associated locus based on the genes’ functional similarity
to genes from other associated loci. Genes that are highly similar
to genes from other loci obtain low prioritization P values, and
simulated GWAS results are used to adjust for gene length
bias as well as other potential confounders. There can be several
prioritized genes in a given locus. Next, DEPICT conducts gene
set enrichment analysis by testing whether genes in associated
loci enrich for reconstituted versions of known pathways, gene
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sets as well as protein complexes. Leveraging the guilt by asso-
ciation hypothesis that genes co-expressing with genes from a
given gene set are likely to be part of that gene set (see Cvejic
et al. (35), for details), the gene set reconstitution is accom-
plished by identifying genes that were co-expressed with genes
in a given gene set based on a panel of 77 840 gene expression
microarrays. Gene sets from the following repositories were
reconstituted: 5984 protein complexes that were derived from
169 810 high-confidence experimentally derived protein–
protein interactions (36); 2473 phenotypic gene sets derived
from 211 882 gene–phenotype pairs from the Mouse Genetics
Initiative (37); 737 Reactome database pathways (38); 184
KEGG database pathways (39); and 5083 Gene Ontology data-
base terms (40). Finally, DEPICT conducts tissue and cell type
enrichment analysis, by testing whether genes in associated
loci are highly expressed in any of 209 Medical Subject
Heading annotations of 37 427 microarrays from the Affymetrix
U133 Plus 2.0 Array platform (see Wood et al. (41) and Geller
et al. (42) for previous applications of DEPICT). In this work,
21 autosomal SNPs for birth length and 44 autosomal SNPs for
infant length were used as input to DEPICT resulting in 21 and
41 non-overlapping loci, respectively, that covered a total of
34 genes and 83 genes, respectively. The gene prioritization,
gene set enrichment and tissue/cell type enrichment analyses
were run using the default settings in DEPICT.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
ACKNOWLEDGEMENTS
Avon Longitudinal Study of Parents And Children (ALSPAC):
We are extremely grateful to all the families who took part in
this study, the midwives for their help in recruiting them, and
the whole ALSPAC team, which includes interviewers, com-
puter and laboratory technicians, clerical workers, research
scientists, volunteers, managers, receptionists and nurses. GWAS
data were generated by Sample Logistics and Genotyping
Facilities at the Wellcome Trust Sanger Institute and LabCorp
(Laboratory Corporation of America) supported by 23andMe.
The Wellcome Trust and Swiss National Science Foundation
funded the expression data. Ethical approval was obtained
from the ALSPAC Law and Ethics Committee and the Local
Ethics Committees. Please note that the study website contains
details of all the data that is available through a fully searchable
data dictionary (http://www.bris.ac.uk/alspac/researchers/data-
access/data-dictionary/).
BAMSE: Supported by the Swedish Research Council, the
Swedish Heart Lung Foundation, the Centre for Allergy
Research (CfA), Stockholm County Council (ALF) and SFO
Program in Epidemiology, KI.
Children’s Hospital Of Philadelphia (CHOP): The authors
thank the network of primary care clinicians and the patients
and families for their contribution to this project and to clini-
cal research facilitated by the Pediatric Research Consortium
(PeRC) at The Children’s Hospital of Philadelphia. R. Chiavacci,
E. Dabaghyan, A. (Hope) Thomas, K. Harden, A. Hill, C. Johnson-
Honesty, C. Drummond, S. Harrison, F. Salley, C. Gibbons,
K. Lilliston, C. Kim, E. Frackelton, F. Mentch, G. Otieno,
K. Thomas, C. Hou, K. Thomas and M.L. Garris provided expert
assistance with genotyping and/or data collection and man-
agement. The authors would also like to thank S. Kristinsson,
L.A. Hermannsson and A. Krisbjo¨rnsson of Rafo¨rninn ehf for
extensive software design and contributions. This research was
financially supported by an Institute Development Award from
the Children’s Hospital of Philadelphia, a Research Develop-
ment Award from the Cotswold Foundation and NIH grant
R01 HD056465.
COPSAC-2000/Registry: We gratefully express our gratitude
to the children and families of the COPSAC2000 cohort study for
all their support and commitment. We acknowledge and appre-
ciate the unique efforts of the COPSAC research team.
Danish National Birth Cohort (DNBC): Support for the
Danish National Birth Cohort was obtained from the Danish
National Research Foundation, the Danish Pharmacists’ Fund,
the EgmontFoundation, theMarchofDimesBirthDefectsFounda-
tion, the Augustinus Foundation and the Health Fund of the
Danish Health Insurance Societies. The generation of GWAS
genotype data for the DNBC samples was carried out within
the GENEVA consortium with funding provided through the NIH
Genes,EnvironmentandHealth Initiative (GEI) (U01HG004423).
Assistance with phenotype harmonization and genotype clean-
ing, as well as with general study coordination, was provided
by the GENEVA Coordinating Center (U01HG004446). Geno-
typing was performed at Johns Hopkins University Center for
Inherited Disease Research, with support from the NIH GEI
(U01HG004438).
The Generation R Study (Generation R): The Generation R
Study is conducted by the Erasmus Medical Center in close
collaboration with the School of Law and Faculty of Social
Sciences of the Erasmus University Rotterdam, the Municipal
Health Service Rotterdam area, Rotterdam, the Rotterdam
Homecare Foundation, Rotterdam and the Stichting Trombose-
dienst & Artsenlaboratorium Rijnmond (STAR-MDC), Rotter-
dam. We gratefully acknowledge the contribution of children
and parents, general practitioners, hospitals, midwives and phar-
macies in Rotterdam. The study protocol was approved by the
Medical Ethical Committee of the Erasmus Medical Centre, Rot-
terdam. Written informed consent was obtained from all partici-
pants. The generation and management of GWAS genotype data
for the Generation R Study were done at the Genetic Laboratory
of the Department of Internal Medicine, Erasmus MC, the
Netherlands. We would like to thank Karol Estrada, Dr Tobias
A. Knoch, Anis Abuseiris, Luc V. de Zeeuw and Rob de Graaf,
for their help in creating GRIMP, BigGRID, MediGRID and
Services@MediGRID/D-Grid, (funded by the German Bundes-
ministerium fuer Forschung und Technology; grants 01 AK 803
A-H, 01 IG 07015 G) for access to their grid computing
resources. We thank Mila Jhamai, Manoushka Ganesh, Pascal
Arp, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters for
their help in creating, managing and QC of the GWAS database.
Also, we thank Karol Estrada for their support in creation and
analysis of imputed data. The Generation R Study is made pos-
sible by financial support from the Erasmus Medical Center, Rot-
terdam, the Erasmus University Rotterdam and the Netherlands
Organization for Health Research and Development.
Hyperglycemia and Adverse Pregnancy Outcome (HAPO)
Study: We are indebted to the participants, investigators and
1164 Human Molecular Genetics, 2015, Vol. 24, No. 4
Downloaded from https://academic.oup.com/hmg/article-abstract/24/4/1155/616707
by kingstonuni user
on 11 December 2017
research staff of the HAPO study at each of the following centers:
Newcastle and Brisbane, Australia; Bridgetown, Barbados;
Toronto, Canada; Hong Kong, Hong Kong; Bangkok, Thailand;
Belfast and Manchester, UK; Bellflower, CA, Chicago, IL,
Cleveland, OH and Providence, RI, USA. This work was sup-
ported by US National Institutes of Health (NIH) grants
(HD34242, HD34243, HG004415 and CA141688) and by the
American Diabetes Association. Genotype cleaning and general
study coordination were provided by the GENEVA Coordinat-
ing Center (U01HG004446). Genotyping was performed at the
Broad Institute of MIT and Harvard, with funding support
from the NIH GEI (U01HG04424), and Johns Hopkins Univer-
sity Center for Inherited Disease Research, with support from the
NIH GEI (U01HG004438) and the NIH contract ‘High through-
put genotyping for studying the genetic contributions to human
disease’ (HHSN268200782096C).
Helsinki Birth Cohort Study (HBCS): The Helsinki Birth
Cohort Study (HBCS/HBCS 1934-44) thanks Professor David
Barker and Tom Forsen. Major financial support was received
from the Academy of Finland (project grants 209072, 129255
grant) and British Heart Foundation. The DNA extraction, sam-
ple quality control, biobank up-keep and aliquoting were per-
formed at the National Institute for Health and Welfare, Helsinki,
Finland.
The INMA Project: This study was funded by grants from
Instituto de Salud Carlos III (Red INMA G03/176 and CB06/
02/0041), FIS-FEDER 03/1615, 04/1509, 04/1112, 04/1931,
05/1079, 05/1052, 06/1213, 07/0314, 09/02647, 11/01007, 11/
02591, 13/02032, 13/1944, PI041436, PI081151, CP11/00178,
97/0588, 00/0021-2, PI061756 and PS0901958, Spanish Minis-
try of Science and Innovation (SAF2008-00357), European
Commission (ENGAGE project and grant agreement HEALTH-
F4-2007-201413), Fundacio´ La Marato´ de TV3, Generalitat de
Catalunya-CIRIT 1999SGR 00241 and Conselleria de Sanitat
Generalitat Valenciana. Part of the DNA extractions and geno-
typing was performed at the Spanish National Genotyping
Centre (CEGEN-Barcelona). The authors are grateful to Silvia
Fochs, Anna Sa`nchez, Maribel Lo´pez, Nuria Pey, Muriel Ferrer,
Amparo Quiles, Sandra Pe´rez, Gemma Leo´n, Elena Romero,
Maria Andreu, Nati Galiana, Maria Dolores Climent and
Amparo Cases for their assistance in contacting the families
and administering the questionnaires. The authors would par-
ticularly like to thank all the participants for their generous col-
laboration. A full roster of the INMA Project Investigators can be
found at http://www.proyectoinma.org/presentacion-inma/lista
do-investigadores/en_listado-investigadores.html.
Leipzig Obesity Childhood Cohort: The Leipzig Childhood
Obesity cohort is supported by grants from Integrated Research
and Treatment Centre (IFB) Adiposity Diseases FKZ: 01EO1001,
from the German Research Foundation for the Clinical Research
Center ‘Obesity Mechanisms’ CRC1052/1 C05. We are grateful
to all the patients and families for contributing to the study. We
highly appreciate the support of the Obesity Team and Auxo
Team of the Leipzig University Children’s Hospital for manage-
ment of the patients and to the Pediatric Research Center Lab
Team for support with DNA banking.
Lifestyle—Immune System—Allergy (LISA) Study Munich:
Generation of GWA data in the LISAplus study in Munich
were covered by Helmholtz Zentrum Munich, Helmholtz Cen-
tre for Environmental Research. In addition, this work was
supported by the Kompetenznetz Adipositas (Competence Net-
work Obesity) funded by the Federal Ministry of Education and
Research (FKZ: 01GI1121A).The authors thank all families for
participation in the study; the obstetric units for allowing recruit-
ment and the LISA study teams for excellent work.
Manchester Asthma and Allergy Study (MAAS): We would
like to thank the children and their parents for their continued
support and enthusiasm. We greatly appreciate the commitment
they have given to the project. We would also like to acknow-
ledge the hard work and dedication of the study team
(post-doctoral scientists, research fellows, nurses, physiologists,
technicians and clerical staff). MAAS was supported by the
Asthma UK Grants No 301 (1995–1998), No 362 (1998–
2001), No 01/012 (2001–2004), No 04/014 (2004–2007) and
The Moulton Charitable Foundation (2004-current); age
11 years clinical follow-up is funded by the Medical Research
Council (MRC) Grant G0601361.
Norwegian Mother Child Cohort (MoBa): his work was sup-
ported by grants from the Norwegian Research Council (FUGE
183220/S10, FRIMEDKLI-05 ES236011), Swedish Medical
Society (SLS 2008-21198), Jane and Dan Olsson Foundations
and Swedish government grants to researchers in the public
health service (ALFGBG-2863, ALFGBG-11522), and the Euro-
pean Community’s Seventh Framework Programme (FP7/2007–
2013), ENGAGE Consortium, grant agreement HEALTH-
F4-2007–201413. The Norwegian Mother and Child Cohort
Study was also supported by the Norwegian Ministry of Health
and the Ministry of Education and Research, NIH/NIEHS (con-
tract no. N01-ES-75558), NIH/NINDS (grant no.1 UO1 NS
047537-01 and grant no.2 UO1 NS 047537-06A1), and the Nor-
wegian Research Council/FUGE (grant no. 151918/S10). We
are grateful to all the participating families in Norway who
take part in this ongoing cohort study. Researchers interested
in using MoBa data must obtain approval from the Scientific
Management Committee of MoBa and from the Regional Com-
mittee for Medical and Health Research Ethics for access to data
and biological material.
Northern Finland Birth Cohort 1966 (NFBC1966) and 1985–
1986 (NFBC1986): We acknowledge late Professor Paula Ran-
takallio (launch of NFBC1966 and initial data collection), Ms
Sarianna Vaara (data collection), Ms Tuula Ylitalo (administra-
tion), Mr Markku Koiranen (data management), Ms Outi Torn-
wall and Ms Minttu Jussila (DNA biobanking).
The PANIC Study: We thank the voluntary children and their
families who participated in The PANIC Study. The study proto-
col was approved by the Research Ethics Committee of the Hos-
pital District of Northern Savo. All children and their parents
gave their informed written consent. The PANIC Study has been
financially supported by grants from the Ministry of Social
Affairs and Health of Finland, the Ministry of Education and
Culture of Finland, the University of Eastern Finland, the Finnish
Innovation Fund Sitra, the Social Insurance Institution of Finland,
the Finnish Cultural Foundation, the Juho Vainio Foundation, the
Foundation for Paediatric Research, the Paulo Foundation, the
Paavo Nurmi Foundation, the Diabetes Research Foundation,
Kuopio University Hospital (EVO-funding number 5031343) and
the Research Committee of the Kuopio University Hospital Catch-
ment Area for the State Research Funding.
The prevention and incidence of asthma and mite allergy birth
cohort study (PIAMA1 and PIAMA2): The PIAMA birth cohort
Human Molecular Genetics, 2015, Vol. 24, No. 4 1165
Downloaded from https://academic.oup.com/hmg/article-abstract/24/4/1155/616707
by kingstonuni user
on 11 December 2017
study is a collaboration of the Institute for Risk Assessment
Sciences, University Utrecht (B. Brunekreef), Julius Center for
Health Sciences and Primary Care, University Medical Center
Utrecht (H.A. Smit), Centre for Prevention and Health Services
Research, National Institute for Public Health and the Environ-
ment, Bilthoven (A.H. Wijga), Department of Pediatrics, Div-
ision of Respiratory Medicine, Erasmus MC-Sophia, Rotterdam
(J.C.d.J.), the Departments of Epidemiology (M.K.), Pulmonol-
ogy (D.S.P.) and Pediatric Pulmonology and Pediatric Allergol-
ogy (G.H.K.) of the University Medical Center Groningen and
the Department of Immunopathology, Sanquin Research, Am-
sterdam (R.C. Aalberse), the Netherlands. The study team grate-
fully acknowledges the participants in the PIAMA birth cohort
study, and all coworkers who helped conducting the medical
examinations, field work and data management. The PIAMA
study was funded by grants from the Dutch Asthma Foundation
(grant 3.4.01.26, 3.2.06.022, 3.4.09.081 and 3.2.10.085CO), the
ZON-MW Netherlands Organization for Health Research and
Development (grant 912-03-031), the Stichting Astmabestrijd-
ing andtheMinistryof theEnvironment.Genome-widegenotyping
was funded by the European Commission as part of GABRIEL
(a multidisciplinary study to identify the genetic and environmental
causes of asthma in the European Community) contract number
018996 under the Integrated Program LSH-2004-1.2.5-1 Post
genomic approaches to understand the molecular basis of asthma
aiming at a preventive or therapeutic control.
The Western Australian Pregnancy (RAINE) Cohort: The
authors are grateful to the Raine Study participants and their fam-
ilies, and to the Raine Study research staff for cohort coordin-
ation and data collection. The authors gratefully acknowledge
the NH&MRC for their long-term contribution to funding the
study over the last 20 years and also the following Institutions
for providing funding for Core Management of the Raine
Study: The University of Western Australia (UWA), Raine
Medical Research Foundation, UWA Faculty of Medicine, Den-
tistry and Health Sciences, The Telethon Institute for Child
Health Research, Curtin University and Women and Infants Re-
search Foundation. The authors gratefully acknowledge the as-
sistance of the Western Australian DNA Bank (National
Health and Medical Research Council of Australia National En-
abling Facility). The authors also acknowledge the support of the
National Health and Medical Research Council of Australia
(Grant ID 403981 and ID 003209) and the Canadian Institutes
of Health Research (Grant ID MOP-82893). The study was con-
ducted with appropriate institutional ethics approval, and written
informed consent was obtained from mothers at all follow-ups
and participants at the year 17 follow-up.
Special Turku Coronary Risk Factor Intervention Project
(Strip): The study was approved by the Joint Commission on
Ethics of the Turku University and the Turku University Central
Hospital. Informed consent was obtained from all parents at the
beginning of the trial and from the children at 15 years of age.
The STRIP study was financially supported by Academy of
Finland (grants 206374 and 251360); Juho Vainio Foundation;
Finnish Cardiac Research Foundation; Finnish Cultural Founda-
tion; Finnish Ministry of Education and Culture; Sigrid Juselius
Foundation; Yrjo¨ Jahnsson Foundation; C.G. Sundell Founda-
tion; Special Governmental Grants for Health Sciences Re-
search, Turku University Hospital; Foundation for Pediatric
Research; and Turku University Foundation.
TEENAGE: TEENAGE study has been co-financed by the
European Union (European Social Fund—ESF) and Greek na-
tional funds through the Operational Program ‘Education and
Lifelong Learning’ of the National Strategic Reference Frame-
work (NSRF)—Research Funding Program: Heracleitus II
Investing in knowledge society through the European Social
Fund. This work was funded by the Wellcome Trust (098051).
We would like to thank all study participants and their families
as well as all volunteers for their contribution in this study. We
thank the following staff from the Sample Management and
Genotyping Facilities at the Wellcome Trust Sanger Institute
for sample preparation, quality control and genotyping: Dave
Jones, Doug Simpkin, Emma Gray, Hannah Blackburn, Sarah
Edkins.
Berlin Birth Cohort (BBC): The Berlin Birth Cohort study was
funded by the Deutsche Forschungsgemeinschaft (DFG), Else
Kro¨ner-Fresenius Foundation, Jacksta¨dt-Foundation and a re-
search grant of the University of Potsdam, Germany. Details of
the study are provided in refs (43–45). We deeply acknowledge
the contribution of the participating families. Replication geno-
typing was supported by ENGAGE Framework VII HEALTH-
F4-2007-201413 and Wellcome Trust 098381.
Diabetes Prediction and Prevention (DIPP): The DIPP study
was supported by the following grants: International: Juvenile
Diabetes Research Foundation International (grants 4-1998-
274, 4-1999-731, 4-2001-435); European Union (grant BMH4-
CT98-3314); Novo Nordisk Foundation; the Academy of Finland
(Decision No. 250124 and Centre of Excellence in Molecular
Systems Immunology and Physiology Research 2012–2017, Deci-
sion No. 250114), the Sigrid Juse´lius Foundation, and the Special
Research Funds for University Hospitals in Finland. We thank
the participating DIPP families and the DIPP staff.
Exeter Family Study Of Childhood Health (EFSOCH): The
EFSOCH study was supported by South West NHS Research
and Development, Exeter NHS Research and Development,
the Darlington Trust, and the Peninsula NIHR Clinical Research
Facility at the University of Exeter. We are extremely grateful to
the EFSOCH study participants and the EFSOCH study team.
The opinions given in this paper do not necessarily represent
those of NIHR, the NHS or the Department of Health. Genotyp-
ing of EFSOCH DNA samples was supported by Diabetes UK
grant RD08/0003692. The local research ethics committees
approved the study, and all adult participants gave informed
written consent.
Singapore Cohort study Of the Risk factors for Myopia study
(SCORM): This study is supported by the National Medical Re-
search Council Grant NMRC/0695/2002, Singapore.
Southampton Women’’s Survey (SWS): The SWS was funded
by the Medical Research Council Of Great Britain, the British
Heart Foundation, the European Union Framework 7 Pro-
gramme, the NIHR Nutrition Biomedical Research Centre, Uni-
versity of Southampton, and Arthritis Research UK. We thank
the mothers of the Southampton Women’s Survey who gave us
their time and the team of dedicated research nurses and ancillary
staff for their assistance.
Netherlands Twin Register (NTR): This project was supported
by ARRA RC2 2MH08995; the European Research Council
(Genetics of Mental Illness, ERC-230374); Spinozapremie
(NWO/SPI 56-464-14192) and Twin-family database for behav-
ior genetics and genomics studies (NWO 480-04-004).
1166 Human Molecular Genetics, 2015, Vol. 24, No. 4
Downloaded from https://academic.oup.com/hmg/article-abstract/24/4/1155/616707
by kingstonuni user
on 11 December 2017
Conflict of Interest statement. None declared.
FUNDING
R.M.F. is supported by a Sir Henry Wellcome Postdoctoral
Fellowship (Wellcome Trust grant 085541/Z/08/Z). T.H.P. is
supported by The Danish Council for Independent Research
Medical Sciences (FSS) The Alfred Benzon Foundation. B.F.
is supported by an Oak Foundation fellowship. M.M. is a
Wellcome Trust Senior Investigator (Wellcome Trust grant
090532) and a NIHR Senior Investigator. T.M.F. is supported
by the European Research Council grant: SZ-245 50371-
GLUCOSEGENES-FP7-IDEAS-ERC. F.R. (VIDI 016.136.367)
and V.W.V.J. (VIDI 016.136.361) received grants from the
Netherlands Organization for Health Research and Deve-
lopment. The other authors did not receive funding for this
manuscript.
REFERENCES
1. Paternoster, L., Howe, L.D., Tilling, K., Weedon, M.N., Freathy, R.M.,
Frayling, T.M., Kemp, J.P., Smith, G.D., Timpson, N.J., Ring, S.M. et al.
(2011) Adult height variants affect birth length and growth rate in children.
Hum. Mol. Genet., 20, 4069–4075.
2. Freathy, R.M., Mook-Kanamori, D.O., Sovio, U., Prokopenko, I., Timpson,
N.J., Berry, D.J., Warrington, N.M., Widen, E., Hottenga, J.J., Kaakinen, M.
et al. (2010) Variants in ADCY5 and near CCNL1 are associated with fetal
growth and birth weight. Nat. Genet., 42, 430–435.
3. Horikoshi, M., Yaghootkar, H., Mook-Kanamori, D.O., Sovio, U., Taal,
H.R., Hennig, B.J., Bradfield, J.P., St Pourcain, B., Evans, D.M., Charoen, P.
et al. (2013) New loci associated with birth weight identify genetic links
between intrauterine growth and adult height and metabolism. Nat. Genet.,
45, 76–82.
4. Mook-Kanamori, D.O., van Beijsterveldt, C.E., Steegers, E.A., Aulchenko,
Y.S., Raat, H., Hofman, A., Eilers, P.H., Boomsma, D.I. and Jaddoe, V.W.
(2012) Heritability estimates of body size in fetal life and early childhood.
PLoS One, 7, e39901.
5. Lango Allen, H., Estrada, K., Lettre, G., Berndt, S.I., Weedon, M.N.,
Rivadeneira, F., Willer, C.J., Jackson, A.U., Vedantam, S., Raychaudhuri, S.
et al. (2010) Hundreds of variants clustered in genomic loci and biological
pathways affect human height. Nature, 467, 832–838.
6. Woods, K.A., Camacho-Hubner, C., Savage, M.O. and Clark, A.J. (1996)
Intrauterine growth retardation and postnatal growth failure associated with
deletion of the insulin-like growth factor I gene. N. Engl. J. Med., 335,
1363–1367.
7. Abuzzahab, M.J., Schneider, A., Goddard, A., Grigorescu, F., Lautier, C.,
Keller, E., Kiess, W., Klammt, J., Kratzsch, J., Osgood, D. et al. (2003) IGF-I
receptor mutations resulting in intrauterine and postnatal growth retardation.
N. Engl. J. Med., 349, 2211–2222.
8. Ward, L.D. and Kellis, M. (2012) HaploReg: a resource for exploring
chromatin states, conservation, and regulatory motif alterations within sets
of genetically linked variants. Nucleic Acids Res., 40, D930–e39934.
9. Liang, L., Morar, N., Dixon, A.L., Lathrop, G.M., Abecasis, G.R., Moffatt,
M.F. and Cookson, W.O. (2013) A cross-platform analysis of 14 177
expression quantitative trait loci derived from lymphoblastoid cell lines.
Genome Res., 23, 716–726.
10. Granell, R., Henderson, A.J., Timpson, N., St Pourcain, B., Kemp, J.P., Ring,
S.M., Ho, K., Montgomery, S.B., Dermitzakis, E.T., Evans, D.M. et al.
(2013) Examination of the relationship between variation at 17q21 and
childhood wheeze phenotypes. J. Allergy Clin. Immunol., 131, 685–694.
11. Jaddoe, V.W., van Duijn, C.M., Franco, O.H., van der Heijden, A.J., van
Iizendoorn, M.H., de Jongste, J.C., van der Lugt, A., Mackenbach, J.P., Moll,
H.A., Raat, H. et al. (2012) The Generation R Study: design and cohort
update 2012. Eur. J. Epidemiol., 27, 739–756.
12. Taal, H.R., St Pourcain, B., Thiering, E., Das, S., Mook-Kanamori, D.O.,
Warrington, N.M., Kaakinen, M., Kreiner-Moller, E., Bradfield, J.P.,
Freathy, R.M. et al. (2012) Common variants at 12q15 and 12q24 are
associated with infant head circumference. Nat. Genet., 44, 532–538.
13. Weedon, M.N., Lango, H., Lindgren, C.M., Wallace, C., Evans, D.M.,
Mangino, M., Freathy, R.M., Perry, J.R., Stevens, S., Hall, A.S. et al. (2008)
Genome-wide association analysis identifies 20 loci that influence adult
height. Nat. Genet., 40, 575–583.
14. Kukita, T., Wada, N., Kukita, A., Kakimoto, T., Sandra, F., Toh, K., Nagata,
K., Iijima, T., Horiuchi, M., Matsusaki, H. et al. (2004) RANKL-induced
DC-STAMP is essential for osteoclastogenesis. J. Exp. Med., 200, 941–946.
15. Yagi, M., Miyamoto, T., Sawatani, Y., Iwamoto, K., Hosogane, N., Fujita,
N., Morita, K., Ninomiya, K., Suzuki, T., Miyamoto, K. et al. (2005)
DC-STAMP is essential for cell–cell fusion in osteoclasts and foreign body
giant cells. J Exp Med, 202, 345–351.
16. Jansen, B.J., Eleveld-Trancikova, D., Sanecka, A., van Hout-Kuijer, M.,
Hendriks, I.A., Looman, M.G., Leusen, J.H. and Adema, G.J. (2009) OS9
interacts with DC-STAMP and modulates its intracellular localization in
response to TLR ligation. Mol. Immunol., 46, 505–515.
17. Manavathi, B., Lo, D., Bugide, S., Dey, O., Imren, S., Weiss, M.J. and
Humphries, R.K. (2012) Functional regulation of pre-B-cell leukemia
homeobox interacting protein 1 (PBXIP1/HPIP) in erythroid differentiation.
J. Biol. Chem., 287, 5600–5614.
18. Stone, D.L., Tayebi, N., Orvisky, E., Stubblefield, B., Madike, V. and
Sidransky, E. (2000) Glucocerebrosidase gene mutations in patients with
type 2 Gaucher disease. Hum. Mutat., 15, 181–188.
19. Sidransky, E., Nalls, M.A., Aasly, J.O., Aharon-Peretz, J., Annesi, G.,
Barbosa, E.R., Bar-Shira, A., Berg, D., Bras, J., Brice, A. et al. (2009)
Multicenter analysis of glucocerebrosidase mutations in Parkinson’s
disease. N. Engl. J. Med., 361, 1651–1661.
20. Chahine, L.M., Qiang, J., Ashbridge, E., Minger, J., Yearout, D., Horn, S.,
Colcher, A., Hurtig, H.I., Lee, V.M., Van Deerlin, V.M. et al. (2013) Clinical
and biochemical differences in patients having Parkinson disease with vs
without GBA mutations. JAMA Neurol., 70, 852–858.
21. Nalls, M.A., Duran, R., Lopez, G., Kurzawa-Akanbi, M., McKeith, I.G.,
Chinnery, P.F., Morris, C.M., Theuns, J., Crosiers, D., Cras, P. et al. (2013) A
multicenter study of glucocerebrosidase mutations in dementia with Lewy
bodies. JAMA Neurol., 70, 727–735.
22. Inoue, D., Reid, M., Lum, L., Kratzschmar, J., Weskamp, G., Myung, Y.M.,
Baron, R. and Blobel, C.P. (1998) Cloning and initial characterization of
mouse meltrin beta and analysis of the expression of four metalloprotease-
disintegrins in bone cells. J. Biol. Chem., 273, 4180–4187.
23. Marzia, M., Guaiquil, V., Horne, W.C., Blobel, C.P., Baron, R. and
Chiusaroli, R. (2011) Lack of ADAM15 in mice is associated with increased
osteoblast function and bone mass. Biol. Chem., 392, 877–885.
24. Johnson, T.S., Engstrom, J.L., Warda, J.A., Kabat, M. and Peters, B. (1998)
Reliability of length measurements in full-term neonates. J. Obstet. Gynecol.
Neonatal. Nurs., 27, 270–276.
25. Vasan, R.S., Glazer, N.L., Felix, J.F., Lieb, W., Wild, P.S., Felix, S.B.,
Watzinger, N., Larson, M.G., Smith, N.L., Dehghan, A. et al. (2009) Genetic
variants associated with cardiac structure and function: a meta-analysis and
replication of genome-wide association data. JAMA, 302, 168–178.
26. Voight, B.F., Scott, L.J., Steinthorsdottir, V., Morris, A.P., Dina, C., Welch,
R.P., Zeggini, E., Huth, C., Aulchenko, Y.S., Thorleifsson, G. et al. (2010)
Twelve type 2 diabetes susceptibility loci identified through large-scale
association analysis. Nat. Genet., 42, 579–589.
27. Ikram, M.A., Fornage, M., Smith, A.V., Seshadri, S., Schmidt, R., Debette,
S., Vrooman, H.A., Sigurdsson, S., Ropele, S., Taal, H.R. et al. (2012)
Common variants at 6q22 and 17q21 are associated with intracranial
volume. Nat. Genet., 44, 539–544.
28. Li, Y., Willer, C.J., Ding, J., Scheet, P. and Abecasis, G.R. (2010) MaCH:
using sequence and genotype data to estimate haplotypes and unobserved
genotypes. Genet. Epidemiol., 34, 816–834.
29. Marchini, J., Howie, B., Myers, S., McVean, G. and Donnelly, P. (2007) A
new multipoint method for genome-wide association studies by imputation
of genotypes. Nat. Genet., 39, 906–913.
30. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender,
D., Maller, J., Sklar,P., de Bakker, P.I., Daly, M.J. et al. (2007) PLINK: a tool
set for whole-genome association and population-based linkage analyses.
Am. J. Hum. Genet., 81, 559–575.
31. Aulchenko, Y.S., Struchalin, M.V. and van Duijn, C.M. (2010) ProbABEL
package for genome-wide association analysis of imputed data. BMC
Bioinformatics, 11, 134.
32. Estrada, K., Abuseiris, A., Grosveld, F.G., Uitterlinden, A.G., Knoch, T.A.
and Rivadeneira, F. (2009) GRIMP: a web- and grid-based tool for
high-speed analysis of large-scale genome-wide association using imputed
data. Bioinformatics, 25, 2750–2752.
Human Molecular Genetics, 2015, Vol. 24, No. 4 1167
Downloaded from https://academic.oup.com/hmg/article-abstract/24/4/1155/616707
by kingstonuni user
on 11 December 2017
33. Devlin, B. and Roeder, K. (1999) Genomic control for association studies.
Biometrics, 55, 997–1004.
34. Willer, C.J., Li, Y. and Abecasis, G.R. (2010) METAL: fast and efficient
meta-analysis of genomewide association scans. Bioinformatics, 26,
2190–2191.
35. Cvejic, A., Haer-Wigman, L., Stephens, J.C., Kostadima, M., Smethurst,
P.A., Frontini, M., van den Akker, E., Bertone, P., Bielczyk-Maczynska, E.,
Farrow, S. et al. (2013) SMIM1 underlies the Vel blood group and influences
red blood cell traits. Nat. Genet., 45, 542–545.
36. Lage, K., Karlberg, E.O., Storling, Z.M., Olason, P.I., Pedersen, A.G.,
Rigina, O., Hinsby, A.M., Tumer, Z., Pociot, F., Tommerup, N. et al. (2007)
A human phenome–interactome network of protein complexes implicated
in genetic disorders. Nat. Biotechnol., 25, 309–316.
37. Bult, C.J., Richardson, R.J., Blake, J.A., Kadin, J.A., Ringwald, M. and Eppig,
J.T. (2000) The Mouse Genome Database Group. Mouse genome informatics
in a new age of biological inquiry. Proceedings of the IEEE International
Symposium on Bio-Informatics and Biomedical Engineering. 29–32.
38. Croft, D., O’Kelly, G., Wu, G., Haw, R., Gillespie, M., Matthews, L., Caudy,
M., Garapati, P., Gopinath, G., Jassal, B. et al. (2011) Reactome: a database
of reactions, pathways and biological processes. Nucleic Acids Res., 39,
D691–D697.
39. Kanehisa, M., Goto, S., Sato, Y., Furumichi, M. and Tanabe, M. (2012)
KEGG for integration and interpretation of large-scale molecular data sets.
Nucleic Acids Res., 40, D109–D114.
40. Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M.,
Davis, A.P., Dolinski, K., Dwight, S.S., Eppig, J.T. et al. (2000) Gene
ontology: tool for the unification of biology. The Gene Ontology
Consortium. Nat. Genet., 25, 25–29.
41. Wood, A.R., Esko, T., Yang, J., Vedantam, S., Pers, T.H., Gustafsson, S.,
Chu, A.Y., Estrada, K., Luan, J., Kutalik, Z. et al. (2014) Defining the role of
common variation in the genomic and biological architecture of adult human
height. Nat. Genet., doi: 10.1038/ng.3097.
42. Geller, F., Feenstra, B., Carstensen, L., Pers, T.H., van Rooij, I.A., Korberg,
I.B., Choudhry, S., Karjalainen, J.M., Schnack, T.H., Hollegaard, M.V. et al.
(2014) Genome-wide association analyses identify variants in
developmental genes associated with hypospadias. Nat. Genet.
43. Hocher, B., Chen, Y.P., Schlemm, L., Burdack, A., Li, J., Halle, H., Pfab, T.,
Kalk, P., Lang, F. and Godes, M. (2009) Fetal sex determines the impact of
maternal PROGINS progesterone receptor polymorphism on maternal
physiology during pregnancy. Pharmacogenet Genomics, 19, 710–718.
44. Pfab, T., Slowinski,T., Godes, M., Halle, H., Priem, F. and Hocher, B. (2006)
Low birth weight, a risk factor for cardiovascular diseases in later life, is
already associated with elevated fetal glycosylated hemoglobin at birth.
Circulation, 114, 1687–1692.
45. Hocher, B., Slowinski, T., Stolze, T., Pleschka, A., Neumayer, HH. and
Halle, H. (2000) Association of maternal G protein beta3 subunit 825T allele
with low birthweight. Lancet, 355, 1241–1242.
1168 Human Molecular Genetics, 2015, Vol. 24, No. 4
Downloaded from https://academic.oup.com/hmg/article-abstract/24/4/1155/616707
by kingstonuni user
on 11 December 2017
